Verona Pharma (VRNA) Price & Analysis

Compare

859 Followers

VRNA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$27.54 - $106.45

Previous CloseN/A

Volume658.49K

Average Volume (3M)1.42M

Market Cap

$9.15B

Enterprise Value$8.40B

Total Cash (Recent Filing)$438.02M

Total Debt (Recent Filing)$244.37M

Price to Earnings (P/E)―

Beta1.62

Next Earnings

Nov 11, 2025

EPS Estimate

0.14

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding86,495,865

10 Day Avg. Volume1,461,221

30 Day Avg. Volume1,421,602

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.92

Enterprise Value/Revenue37.91

Enterprise Value/Gross Profit39.84

Enterprise Value/Ebitda-229.61

Forecast

1Y Price Target

$107.00

Price Target Upside0.29% Upside

Rating ConsensusHold

Number of Analyst Covering10

Bulls Say, Bears Say

Bulls Say

Market PotentialOhtuvayre could have generated peak annual sales approaching $3B in COPD alone, with additional potential in other indications like NCFBE.

Pipeline StrengthOhtuvayre is a good fit for Merck and will help to strengthen Merck's growing cardio-pulmonary pipeline and portfolio.

Product LaunchOhtuvayre has established strong revenue growth, showing a fast adoption among physicians and patients.

Bears Say

Financial PerformanceIncreased costs have been modeled, resulting in a reduction in net income for 2025.

Guideline MentionDespite inclusion in the GOLD treatment guidelines for COPD, Ohtuvayre is only briefly mentioned with weak language.

Stock DowngradeIn the wake of the deal announcement, the rating was downgraded to Neutral from the prior Buy.

Verona Pharma News

Verona Pharma shareholders approve proposed acquisition by Merck

Verona Pharma (VRNA) announced its shareholders have approved the proposal for Merck (MRK) to acquire the company for...

2d ago

MRK

VRNA

Verona Pharma Shareholders Approve Merck Acquisition

Verona Pharma ( ($VRNA) ) has provided an update. On September 24, 2025, Verona Pharma‘s shareholders approved the...

2d ago

VRNA

Verona Pharma Extends Severance Benefits Amid Merck Deal

Verona Pharma ( ($VRNA) ) has issued an announcement. On September 5, 2025, Verona Pharma‘s Board of Directors...

17d ago

VRNA

Verona Pharma’s New COPD Study: What Investors Need to Know

Verona Pharma (UK) (($GB:VRP)), Verona Pharma (($VRNA)) announced an update on their ongoing clinical study. Verona Pharma is...

1M ago

VRNA

Verona Pharma’s New COPD Study: A Potential Game-Changer?

Verona Pharma (UK) (($GB:VRP)), Verona Pharma (($VRNA)) announced an update on their ongoing clinical study. Verona Pharma has...

1M ago

VRNA

Verona Pharma downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju downgraded Verona Pharma (VRNA) to Neutral from Buy with a price target of...

2M ago

VRNA

Verona Pharma downgraded to Neutral from Overweight at Piper Sandler

Piper Sandler downgraded Verona Pharma (VRNA) to Neutral from Overweight with a price target of $107, down from...

3M ago

VRNA

Verona Pharma downgraded to Hold from Buy at Truist

Truist downgraded Verona Pharma (VRNA) to Hold from Buy with a price target of $107, up from $100,...

3M ago

MRK

VRNA

Verona Pharma downgraded to Peer Perform from Outperform at Wolfe Research

Wolfe Research downgraded Verona Pharma (VRNA) to Peer Perform from Outperform without a price target after Merck (MRK)...

3M ago

VRNA

Verona Pharma downgraded to Neutral from Buy at Roth Capital

Roth Capital analyst Boobalan Pachaiyappan downgraded Verona Pharma (VRNA) to Neutral from Buy with a price target of...

3M ago

VRNA

Verona Pharma Stock (VRNA) Soars 20% on $10B Merck Deal

Verona Pharma stock soared on Wednesday after the Ohtuvayre maker announced a $10 billion deal with Merck. ...

3M ago

MRK

VRNA

Verona Pharma downgraded to Neutral from Buy at BTIG

BTIG downgraded Verona Pharma (VRNA) to Neutral from Buy without a price target after Merck (MRK) announced it...

3M ago

VRNA

Verona Pharma downgraded to Equal Weight from Overweight at Wells Fargo

Wells Fargo downgraded Verona Pharma (VRNA) to Equal Weight from Overweight with a price target of $107, down...

3M ago

MRK

VRNA

Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!

Investors will find plenty of stock market stories to read today with the TipRanks daily wrap-up. ...

3M ago

AMD

MRK

VRNA FAQ

What was Verona Pharma Plc’s price range in the past 12 months?

Verona Pharma Plc lowest stock price was $27.54 and its highest was $106.45 in the past 12 months.

What is Verona Pharma Plc’s market cap?

Verona Pharma Plc’s market cap is $9.15B.

When is Verona Pharma Plc’s upcoming earnings report date?

Verona Pharma Plc’s upcoming earnings report date is Nov 11, 2025 which is in 46 days.

How were Verona Pharma Plc’s earnings last quarter?

Verona Pharma Plc released its earnings results on Jul 31, 2025. The company reported -$0.005 earnings per share for the quarter, missing the consensus estimate of $0.029 by -$0.034.

Is Verona Pharma Plc overvalued?

According to Wall Street analysts Verona Pharma Plc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Verona Pharma Plc pay dividends?

Verona Pharma Plc does not currently pay dividends.

What is Verona Pharma Plc’s EPS estimate?

Verona Pharma Plc’s EPS estimate is 0.14.

How many shares outstanding does Verona Pharma Plc have?

Verona Pharma Plc has 86,495,865 shares outstanding.

What happened to Verona Pharma Plc’s price movement after its last earnings report?

Verona Pharma Plc reported an EPS of -$0.005 in its last earnings report, missing expectations of $0.029. Following the earnings report the stock price went down -0.048%.

Which hedge fund is a major shareholder of Verona Pharma Plc?

Currently, no hedge funds are holding shares in VRNA

Verona Pharma Stock Smart Score

Neutral

Fundamentals

Return on Equity

-36.38%

Trailing 12-Months

Asset Growth

31.96%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Verona Pharma Plc

Verona Pharma (VRNA) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases. The company is primarily involved in the research and development of novel compounds that target unmet medical needs in conditions such as chronic obstructive pulmonary disease (COPD) and asthma. Verona Pharma's lead product candidate, ensifentrine, is an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, designed to improve lung function and reduce inflammation.

Verona Pharma (VRNA) Earnings & Revenues

Historic Earnings Reports

VRNA Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlights significant achievements such as the strong launch of O2VERE, robust financial performance, and strategic advancements in pipeline and market expansion. However, challenges remain with operating losses and seasonality impacts. Overall, the positive developments and financial strength present an optimistic outlook for the company.View all VRNA earnings summaries

VRNA Stock 12 Month Forecast

Average Price Target

$107.00

▲(0.29% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","61":"$61","108":"$108","37.5":"$37.5","84.5":"$84.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":107,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$107.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":107,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$107.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":107,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$107.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,37.5,61,84.5,108],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,90.48,91.75076923076924,93.02153846153847,94.2923076923077,95.56307692307692,96.83384615384615,98.10461538461539,99.37538461538462,100.64615384615385,101.91692307692308,103.18769230769232,104.45846153846153,105.72923076923077,{"y":107,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,90.48,91.75076923076924,93.02153846153847,94.2923076923077,95.56307692307692,96.83384615384615,98.10461538461539,99.37538461538462,100.64615384615385,101.91692307692308,103.18769230769232,104.45846153846153,105.72923076923077,{"y":107,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,90.48,91.75076923076924,93.02153846153847,94.2923076923077,95.56307692307692,96.83384615384615,98.10461538461539,99.37538461538462,100.64615384615385,101.91692307692308,103.18769230769232,104.45846153846153,105.72923076923077,{"y":107,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.51,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.61,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.48,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.99,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.98,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.11,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.44,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.3,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.63,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.54,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.26,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.48,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >